WP1066 and Radiation Therapy in Newly Diagnosed Glioblastoma Patients
Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This is a phase II, open label, multi-arm trial of radiation therapy in combination with
WP1066 in newly diagnosed IDH wild-type, MGMT-unmethylated glioblastoma patients, with
multiple cohorts. Patients will be stratified into Cohort 1 versus Cohort 2 based on gross
total resection (GTR) status.
Cohort 1: Radiation therapy (RT) + WP1066 in glioblastoma patients with gross total resection
Sample size for Cohort 1: Up to 25 patients may be enrolled in order to obtain 21 patients
who are evaluable for the primary objective.
Cohort 2: RT + WP1066 ± optional secondary surgical resection post-RT in glioblastoma
patients without gross total resection who are candidates for non-emergent palliative
surgical resection Sample size for Cohort 2: Up to 14 patients may be enrolled in order to
obtain 10 patients who undergo secondary surgical resection.